Trellis Bioscience discovers and develops novel human antibody therapeutics as treatment for infectious disease and oncology indications. The company leverages its proprietary platform technology, CellSpot™, to find rare human antibodies with superior selectivity, affinity and other characteristics. The company has built a pipeline of monoclonal antibodies focused on infectious disease, with the most advanced being an IND candidate for treatment of Respiratory Syncytial Virus, licensed to Medimmune.

 

Fatal error: Allowed memory size of 33554432 bytes exhausted (tried to allocate 6293991 bytes) in /data/9/2/61/161/2550976/user/2795889/htdocs/core/xpdo/cache/xpdocachemanager.class.php on line 860